Procalcitonin Diagnostics Market Expansion: Rising Focus on Rapid Infection Assessment

Author : Sameer Straits2 | Published On : 04 Nov 2026

The growing need for rapid infection assessment and effective sepsis management is strengthening demand for procalcitonin (PCT) testing across healthcare systems. As hospitals and diagnostic laboratories prioritize timely clinical decisions and responsible antibiotic use, procalcitonin has become an important biomarker in bacterial infection assessment. According to Straits Research, the global procalcitonin market was valued at USD 291.88 million in 2025 and is projected to increase from USD 331.40 million in 2026 to USD 915.26 million by 2034, registering a CAGR of 13.54% during the forecast period 2026–2034.

Procalcitonin testing helps healthcare professionals assess the likelihood and progression of bacterial infections, particularly sepsis and lower respiratory tract infections. Its ability to support treatment decisions and monitor patient responses is expanding its relevance across emergency departments, intensive care units, and diagnostic laboratories.

Rising Sepsis Incidence Strengthens Demand for Procalcitonin Testing

Sepsis remains a major healthcare concern because delayed identification and treatment can lead to severe complications and increased mortality. Procalcitonin levels generally rise in response to bacterial infections, making the biomarker useful in assessing suspected infections and supporting sepsis management.

Hospitals increasingly rely on rapid diagnostic information to evaluate patients and determine appropriate treatment pathways. Procalcitonin testing can help clinicians assess infection severity and monitor treatment response, supporting more informed decisions in acute and critical care environments. These applications are contributing to demand for reliable and timely diagnostic assays.

Antimicrobial Stewardship Encourages Biomarker Adoption

Antimicrobial resistance has increased the importance of responsible antibiotic prescribing across healthcare systems. Procalcitonin-guided protocols can support decisions about antibiotic initiation, continuation, and discontinuation, particularly in respiratory tract infections and critical care settings.

The availability of measurable biomarker information helps clinicians evaluate whether antibiotic treatment remains necessary alongside other clinical findings. This role in antimicrobial stewardship is encouraging hospitals and diagnostic laboratories to integrate procalcitonin assays into infection management protocols. The emphasis on reducing unnecessary antibiotic exposure is expected to support market expansion.

Automated Immunoassay Technologies Improve Testing Efficiency

Chemiluminescence immunoassay (CLIA) represents a leading technology in the procalcitonin market because of its sensitivity, specificity, automation capabilities, and suitability for high-throughput laboratory testing. Automated systems help diagnostic laboratories process larger sample volumes while supporting consistent and timely measurement of procalcitonin levels.

Enzyme-linked fluorescent assay (ELFA) and other testing technologies also contribute to the market. Improvements in assay performance, workflow integration, and laboratory automation are strengthening the availability of PCT testing across hospitals and specialized diagnostic facilities.

Hospitals and Medical Applications Drive Market Demand

Medical applications represent the dominant application segment, supported by the use of procalcitonin testing in bacterial infection assessment, sepsis management, and lower respiratory tract infection monitoring. Hospitals are the leading end-user group because of their need for rapid diagnostic support in emergency and intensive care settings.

Diagnostic laboratories also play an important role by providing testing services to healthcare facilities and clinicians. Meanwhile, point-of-care testing offers opportunities for faster access to diagnostic information, particularly in settings where timely clinical assessment is essential.

North America Leads the Procalcitonin Market

North America accounted for 38.4% of the global procalcitonin market in 2025, supported by established diagnostic infrastructure, awareness of sepsis management, and the availability of advanced immunoassay platforms. The United States represents an important market because of the substantial clinical and economic burden associated with sepsis. Canada also contributes to regional demand through hospital-based infection management and diagnostic testing.

Europe represents another significant regional market, with the United Kingdom and Germany facing considerable sepsis-related healthcare demands. The need to improve early infection assessment, manage treatment costs, and strengthen antimicrobial stewardship supports the adoption of procalcitonin testing across the region.

Industry Developments and Competitive Landscape

Diagnostic technology providers are expanding their procalcitonin testing capabilities through automated immunoassay platforms and improved assay availability. In April 2026, Siemens Healthineers expanded access to procalcitonin testing across its Atellica diagnostic platforms. Roche also broadened the deployment of Elecsys procalcitonin testing through its cobas integrated diagnostic systems in February 2026. Earlier, in May 2025, DiaSys Diagnostic Systems received U.S. FDA 510(k) clearance for its Procalcitonin FS assay and associated calibrators and control materials.

Key participants in the procalcitonin market include Thermo Fisher, Roche Diagnostics, bioMérieux, HyTest, BBI Solutions, ProSpec, Wondfo, Ningbo Medicalsystem Biotechnology, Wuhan Easy Diagnosis Biomedicine, and Snibe. Competition is shaped by assay accuracy, testing speed, platform compatibility, automation, and the ability to serve hospital and laboratory requirements.

Future Outlook

The procalcitonin market is positioned for strong growth as healthcare providers focus on timely infection assessment, sepsis management, and antimicrobial stewardship. Advances in immunoassay technology and wider access to automated diagnostic platforms are expected to strengthen testing capabilities across healthcare settings. With the market projected to reach USD 915.26 million by 2034, procalcitonin testing is expected to remain an important tool supporting clinical decisions in bacterial infection management.

Explore the full market report: https://straitsresearch.com/report/procalcitonin-market

About Straits Research

Straits Research is a market intelligence and consulting firm providing industry analysis, market sizing, competitive assessments, and strategic insights across global industries. Its research supports businesses and decision-makers in identifying market opportunities and making informed strategic decisions.